NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Metagenomi Therapeutics, Inc. (MGX) Stock Analysis

Metagenomi Therapeutics, Inc. (MGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MGX

$0.83

−$0.00 (−0.30%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MGX with… →

MGX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.85
Previous Close
$0.83
Day's Range
0.80–0.86
52-Week Range
0.77–3.21
Volume
85.78K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.70
Valuation
Market Cap
$31.31M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.31
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.49
Financials (FY)
Revenue (FY)
$25.21M−51.79%
Net Income (FY)
−$87.87M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
37.78M
1-Year Return
−73.69%
Dividend and dates
Avg Volume
155.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MGX closed at $0.83, −73.69% over 1 year.

Metagenomi Therapeutics, Inc. (MGX) has a market capitalization of $31.31M.

In fiscal 2025, MGX reported revenue of $25.21M.

MGX Stock Return by Calendar Year

Metagenomi Therapeutics, Inc. (MGX) return since Feb 2024: what $10,000 became

1 year
$10,000 $2,631
−73.69%
Since Feb 2024
$10,000 $804
−91.96%

If you had invested $10,000 in Metagenomi Therapeutics, Inc. (MGX) at the close on February 9, 2024, the earliest close on record here, it would have been worth $804 at the close on October 21, 2026: −91.96% in total, −60.73% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−48.84%
2025−55.12%
2024 (partial year)−64.99%

As of October 21, 2026.

MGX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$25.21M−$87.87M−348.5%
2024$52.30M−$78.06M−149.3%
2023$44.76M−$68.26M−152.5%
2022$17.20M−$43.59M−253.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$25.21M—−$96.01M−$87.87M−348.5%
2024$52.30M—−$88.90M−$78.06M−149.3%
2023$44.76M—−$78.49M−$68.26M−152.5%
2022$17.20M—−$44.64M−$43.59M−253.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MGX Valuation vs Biotechnology Median

Median of 608 stocks
MetricMGXBiotechnology medianvs median
P/S ratio2.3113.300.2x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Metagenomi Therapeutics, Inc. (MGX) is capitalised at $31.31M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 113.

MGX last closed at $0.83 on October 21, 2026. That is $0.00 (−0.30%) against the previous close. Over the past 52 weeks the price has ranged from $0.77 to $3.21. The latest close sits 7.78% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $25.21M. That is −51.79% against the prior fiscal year, when revenue was $52.30M. The same year closed with a net loss of $87.87M. Trailing earnings per share are −2.49.

Across the 4 fiscal years on file, revenue moves from $17.20M in 2022 to $25.21M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.31. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.7. Annualized volatility over the trailing 2 years is 115.5%. The trailing one-year total return is −73.69%. The stored price history starts on February 9, 2024, and the total return since then is −91.96%.

Growth & Income

The record shows no dividend for MGX.

The record holds one complete calendar year, 2025, which returned −55.12%. So far in 2026 the total return is −48.84%.

Peer Comparison

Metagenomi Therapeutics, Inc. (MGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Metagenomi Therapeutics, Inc. MGX $31.31M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Metagenomi Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Visit website →